Armata Pharmaceuticals Inc. (ARMP)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Armata Pharmaceuticals Inc. (ARMP) is up 26.1% since the beginning of the year. At $8 per share, ARMP is trading 51.5% below its 52-week high of $16. Investors who bought $1,000 worth of ARMP shares 5 years ago would now be looking at an investment worth $1,909.

Armata Pharmaceuticals Inc. (ARMP) has returned 26.11% so far this year and 308.25% over the past 12 months. Over the last ten years, ARMP has returned -30.20% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Mar 9, 2011, ARMP's average daily return is +0.15%, while the average monthly return is +0.94%. At this rate, an investment would double in approximately 6.2 years.

Historically, 43% of months were positive and 57% were negative. The best month was Jul 2013 with a return of +191.4%, while the worst month was May 2017 at -72.3%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.

On a daily basis, ARMP closed higher 42% of trading days. The best single day was Nov 17, 2011 with a return of +109.0%, while the worst single day was May 5, 2017 at -58.6%.

Armata Pharmaceuticals Inc. has an annualized alpha of 41.48%, beta of 0.30, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since March 10, 2011.

• This stock participated in 146.90% of S&P 500 Index downside but only -35.06% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.30 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ARMP ranks 92 for risk / return — in the top 92% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Armata Pharmaceuticals Inc. (ARMP) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Armata Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Armata Pharmaceuticals Inc. was 99.98%, occurring on Apr 10, 2025. The portfolio has not yet recovered.

The current Armata Pharmaceuticals Inc. drawdown is 99.84%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Armata Pharmaceuticals Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Armata Pharmaceuticals Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.